Gene Therapy And Accelerated Approval: US FDA Mulls Pooling Data To Shrink Postmarket Studies

 
• By Sarah Karlin-Smith
  
swimming pool with lots of people sitting on side dangling legs in
The FDA wants to make gene therapy postmarket studies more feasible, such as by pooling data from multiple indications. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Post-Marketing Regulation & Studies

More from Product Reviews